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ABSTRACT Neisseria meningitidis is the most common cause of bacterial meningitis
in children and young adults worldwide. A 4-component vaccine against N. meningi-
tidis serogroup B (MenB) disease (MenB-4C [Bexsero]; GSK) combining factor H bind-
ing protein (fHBP), neisserial heparin binding protein (NHBA), neisserial adhesin A
(NadA), and PorA-containing outer membrane vesicles was recently approved for use
in the United States and other countries worldwide. Because the public health im-
pact of MenB-4C in the United States is unclear, we used the meningococcal antigen
typing system (MATS) to assess the strain coverage in a panel of strains representa-
tive of serogroup B (NmB) disease in the United States. MATS data correlate with
killing in the human complement serum bactericidal assay (hSBA) and predict the
susceptibility of NmB strains to killing in the hSBA, the accepted correlate of protec-
tion for MenB-4C vaccine. A panel of 442 NmB United States clinical isolates (col-
lected in 2000 to 2008) whose data were down weighted with respect to the Ore-
gon outbreak was selected from the Active Bacterial Core Surveillance (ABCs; CDC,
Atlanta, GA) laboratory. MATS results examined to determine strain coverage were
linked to multilocus sequence typing and antigen sequence data. MATS predicted
that 91% (95% confidence interval [CI95], 72% to 96%) of the NmB strains causing
disease in the United States would be covered by the MenB-4C vaccine, with the es-
timated coverage ranging from 88% to 97% by year with no detectable temporal
trend. More than half of the covered strains could be targeted by two or more anti-
gens. NHBA conferred coverage to 83% (CI95, 45% to 93%) of the strains, followed
by factor H-binding protein (fHbp), which conferred coverage to 53% (CI95, 46% to
57%); PorA, which conferred coverage to 5.9%; and NadA, which conferred coverage
to 2.5% (CI95, 1.1% to 5.2%). Two major clonal complexes (CC32 and CC41/44) had
99% strain coverage. The most frequent MATS phenotypes (39%) were fHbp and
NHBA double positives. MATS predicts over 90% MenB-4C strain coverage in the
United States, and the prediction is stable in time and consistent among bacterial
genotypes.
IMPORTANCE The meningococcal antigen typing system (MATS) is an enzyme-
linked immunosorbent assay (ELISA)-based system that assesses the levels of expres-
sion and immune reactivity of the three recombinant MenB-4C antigens and, in con-
junction with PorA variable 2 (VR2) sequencing, provides an estimate of the
susceptibility of NmB isolates to killing by MenB-4C-induced antibodies. MATS assays
or similar antigen phenotype analyses assume importance under conditions in which
analyses of vaccine coverage predictions are not feasible with existing strategies, in-
cluding large efficacy trials or functional antibody screening of an exhaustive strain
panel. MATS screening of a panel of NmB U.S. isolates (n  442) predicts high
MenB-4C vaccine coverage in the United States.
Received 14 June 2017 Accepted 12 October
2017 Published 15 November 2017
Citation Rajam G, Stella M, Kim E, Paulos S,
Boccadifuoco G, Serino L, Carlone G, Medini D.
2017. Meningococcal antigen typing system
(MATS)-based Neisseria meningitidis serogroup
B coverage prediction for the MenB-4C vaccine
in the United States. mSphere 2:e00261-17.
https://doi.org/10.1128/mSphere.00261-17.
Editor Michael J. Imperiale, University of
Michigan—Ann Arbor
This is a work of the U.S. Government and is
not subject to copyright protection in the
United States. Foreign copyrights may apply.
Address correspondence to Gowrisankar
Rajam, GRajam@cdc.gov.
* Present address: George Carlone, Palm Coast,
Florida, USA.
Meningococcal Antigen Typing System
(MATS) predicts high MenB-4C vaccine
coverage in US
RESEARCH ARTICLE
Clinical Science and Epidemiology
crossm
November/December 2017 Volume 2 Issue 6 e00261-17 msphere.asm.org 1
KEYWORDS MATS, MenB-4C, NHBA, NadA, Neisseria meningitidis, PorA, SBA, fHbp
Neisseria meningitidis, responsible for a global annual disease burden of ~50,000deaths and as many long-term disabilities, is currently the most common cause of
bacterial meningitis in children and young adults (1, 2). In the United States, serogroup
B (NmB) strains cause approximately 30% of disease in all age groups, including
adolescents, and 60% of cases in infants aged 1 year. Licensed conjugate vaccines
have been successful in reducing the circulation and disease burden of serogroups A,
C, W, and Y (3). However, serogroup B has presented unique challenges in vaccine
development due to the similarity between the NmB capsular polysaccharide and a
human neural cell adhesion molecule, which creates the risk of generating an autoim-
mune reaction (4, 5). The reverse vaccinology approach, starting from the genomic
information determined for the bacterium, has enabled the identification of noncap-
sular protein surface antigens that could help prevent invasive meningococcal disease
(IMD) caused by any capsular serogroup (6, 7). These included neisserial adhesin A
(NadA), neisserial heparin-binding antigen (NHBA), and factor H-binding protein
(fHbp), which, in combination with New Zealand strain outer membrane vesicles (NZ
OMV) harboring the PorA P1.4 antigen, constitute the N. meningitidis serogroup B
4-component (MenB-4C) vaccine (Bexsero; GSK). MenB-4C was the first broad-coverage
MenB vaccine based on recombinant proteins (8) and is the only one approved (in
January 2013) for use in individuals 2 months of age and above by the European
Medicines Agency (8). In January 2015, the U.S. Food and Drug Administration ap-
proved this vaccine for use in persons 10 to 25 years of age. Subsequently, the U.S.
Advisory Committee on Immunization Practices (ACIP) recommended the use of MenB
vaccines for all persons 10 years of age in certain high-risk groups and suggested its
use for adolescents 16 to 23 years of age (9, 10).
Efficacy studies to demonstrate the benefit of meningococcal vaccines are not
feasible due to the relatively low incidence of the disease. Efficacy of glycoconjugate
vaccines against serogroups A, C, Y, and W was estimated using the serum bactericidal
antibody assay with rabbit (rSBA) or human complement (hSBA) (11, 12) accepted as a
surrogate of protection in the clinical evaluation of meningococcal vaccines (13, 14).
Extrapolating this approach to NmB poses significant challenges. The meningococ-
cal genome’s plasticity facilitates adaptation of surface structures to changing environ-
ments through a variety of genetic mechanisms (15–17) and generates a high variability
of sequence and level of surface expression for protein antigens, affecting strain
susceptibility to vaccine-induced antibodies. To predict the effectiveness of a MenB
vaccine, a large panel of bacterial isolates representative of meningococcal disease in
the United States would need to be tested in hSBA versus a significant number of
subjects, thus requiring large volumes of serum and human complement. This would
be a challenging undertaking, especially in infant populations.
To overcome these limitations, the meningococcal antigen typing system (MATS)
was developed and standardized across public health laboratories worldwide (18, 19).
The MATS combines a sandwich enzyme-linked immunosorbent assay (ELISA) to mea-
sure the immunologic cross-reactivity and quantity of antigen expression for three
MenB-4C protein antigens (fHbp, NadA, and NHBA) with genetic typing of the PorA
variable 2 (VR2) region to determine the immune recognition potential for the OMV
component. MATS typing for each antigen correlates with killing in the hSBA and
predicts the susceptibility of NmB strains to killing in the hSBA, i.e., the strain coverage
of the MenB-4C vaccine (18). MATS has been shown to be a conservative predictor of
strain coverage by the MenB-4C vaccine in infants and adolescents (20). In addition,
MATS coverage was shown to correlate with high rates of individual seroprotection
(21).
MATS has been used to predict MenB-4C strain coverage in multiple countries,
including Canada and countries in Europe (22–25), using cross-sectional panels of strain
isolated from meningococcal disease cases in the respective countries during one or
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two epidemiological years. So far, however, the MenB-4C strain coverage has not been
estimated in the United States; neither has the longitudinal stability of such predictions
been examined.
In this study, we evaluated a longitudinal panel of 442 U.S. NmB disease isolates
(collected in 2000 to 2008) that were selected by the Active Bacterial Core Surveillance
(ABCs; CDC) laboratory that are representative of serogroup B meningococcal disease
in the United States (26). MATS analysis was performed on each NmB isolate, and the
results were correlated with antigen genotyping data to determine MenB-4C strain
coverage in the United States and to analyze its longitudinal trends from 2000 to 2008.
RESULTS
PorA VR2 subtype 4, covered by the OMV component of the MenB-4C vaccine (18),
was identified in 23 strains (5.3%), while PorA subtypes 16 and 14 (each approximately
20%) predominated in 2000 to 2008 (Fig. 1A).
Among the NmB U.S. isolates tested, the specific genotype of fHbp protein included
in MenB-4C, variant 1 and peptide 1, was identified in 144 of 442 strains (33%). Among
the fHbp variant 1 results, the most common peptides were peptides 1, 13, and 4 (33%,
7.2%, and 5.0%, respectively) (see Table 2). The most common factor H-binding protein
variant 2 peptides were peptides 19, 24, and 16 (11%, 7.2%, and 5.0%, respectively); all
other variant 2 and 3 peptides were identified in less than 5% of isolates (see Table 2).
MATS detected quantifiable fHbp expression in 262/442 (59%) isolates (Fig. 1B). The
NmB isolates with nonquantifiable MATS relative potencies (RP) for fHbp harbored fHbp
variants 2 and 3, which were not included in the MenB-4C vaccine. NHBA expression
was detected in 440 (95%) NmB isolates with a quantifiable MATS RP. NHBA peptides
5, 20, 10, 29, 3, and 21 were predominant in the U.S. NmB isolates (see Table 3). The
specific genotype of NHBA included in the MenB-4C vaccine is peptide 2. This specific
FIG 1 MenB-4C antigen frequency distribution in NmB U.S. isolates (n  442). (A) Prevalence of PorA VR2 subtypes. Most of the NmB isolates belonged to the
PorA 16 VR2 subtype (20.4%), followed by the PorA 14 VR2 subtype (19.9%). PorA VR2 subtype 4 is expressed in 5.9% of the isolates. (B) Frequency distribution
of fHbp MATS relative potencies (RPs). Among the U.S. NmB isolates tested, 262/442 (59%) expressed fHbp above the MATS lower limit of quantitation (LLOQ)
(gray bars). (C) Frequency distribution of NHBA MATS relative potencies (RPs) among the U.S. NmB isolates (n  442). A total of 440 of the NmB isolates tested
expressed NHBA above the MATS LLOQ (gray bars). (D) Frequency distribution of NadA MATS relative potencies (RPs). Among the U.S. NmB isolates tested, only
132 of 442 (30%) expressed NadA above the MATS LLOQ (gray bars).
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genotype was identified in only 42 of 442 (9.5%) isolates, but MATS demonstrated the
immune reactivity of anti-NHBA antibodies with the majority (n  440) of test isolates,
irrespective of the NHBA genotype (Fig. 1C).
The nadA gene was harbored by 170/442 (39%) strains, and 78% of these isolates
(132/170) expressed NadA with quantifiable MATS RP (Fig. 1D).
Figure 2 summarizes the results of the MenB-4C strain coverage analysis performed.
Results indicated that 91% (95% confidence interval [CI95], 72% to 96%) of the NmB U.S.
isolates are predicted to be covered by the MenB-4C vaccine. While 5.7% (25/442) of the
isolates had three antigens covered (RP  positive bacterial threshold [PBT] and/or
PorA  P1.4), 42% (184/442) and 44% (194/442) had two antigens and one antigen
covered, respectively (Fig. 2A). NHBA alone or in combination with another antigen(s)
FIG 2 MenB-4C vaccine strain coverage potential among the U.S. NmB isolates (n  442). (A) Among the
U.S. NmB isolates tested, 194/442 (44%) expressed one antigen (1Ags), 184/442 (42%) two antigens
(2Ags), and 25/442 (5.7%) three antigens (3Ags) at levels over the PBT thresholds for the respective
antigens. Overall, MATS estimates 91% coverage of the 4CMenB vaccine among U.S. NmB isolates. 0Ags,
no antigens. (B) Contribution of individual antigens to 4CMenB coverage of the U.S. NmB isolates (n 
442). NHBA conferred maximum coverage potentials, with 83% of NHBA-positive strains exhibiting PBT
values over the threshold, followed by fHbp (53%), PorA (5.9%), and NadA (2.5%). (C) Frequency of MATS
phenotypes among the U.S. NmB isolates. The most frequent combination was represented by MATS
double positives for fHbp and NHBA antigens (39%) followed by MATS single positives for NHBA antigen
(36%). The MATS-negative phenotype accounted for 9%.
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had RP values that were greater than the PBT values determined for 83% (CI95, 45% to
93%) of the NmB isolates followed by fHbp with 53% (CI95, 46% to 57%). The propor-
tions of MATS-predicted coverage for PorA and NadA were 5.9% and 2.5% (CI95, 1.1%
to 5.2%), respectively (Fig. 2B). In the case of NadA, the low contribution may have been
due to the growth conditions in use for MATS testing, which repress nadA expression
(27, 28). Having four antigens and two possible states (MATS positive or negative) each,
2416 antigen combinations or MATS phenotypes can be observed. As shown in
Fig. 2C, only 5 of the 16 phenotypes were observed with a frequency of 1%,
accounting overall for 96% of the panel. The most frequent MATS phenotype was the
double-positive phenotype for fHbp and NHBA antigens, followed by NHBA positive,
negative for all antigens, fHbp positive, and triple positive for fHbp, NHBA, and PorA.
Data corresponding to predicted strain coverage by year of strain isolation in the
United States from 2000 to 2008 are shown in Fig. 3 (see also Table S1 in the
supplemental material). Point estimates of predicted strain coverage were similar across
different years, and the 95% CIs largely overlapped. Lower levels of strain coverage
were seen in the isolates collected in 2006 and 2008 (88%) and 2000 (89%); higher
levels of strain coverage were seen in 2001 (97%) and 2004 (95%). A 2-sided chi-square
test was used to test the differences across years in the predicted MATS coverage and
in the upper and lower limit of the 95% CIs. No statistical significant difference across
years was observed (P value  0.567, P value  0.457, and P value  0.654, respec-
tively). A linear regression model was used to test the strain coverage stability over
time, and no statistically significant trend was observed either (P value  0.222;
Table S2), indicating high and consistently stable strain coverage in the United States
over almost a decade.
Data corresponding to the predicted strain coverage classified by clonal complex
(CC) are shown in Table 1. Two major CCs accounting for more than half of the
circulating strains (CC32 and CC41/44) had predicted strain coverage of 99% (CI95, 98%
to 100% and 73% to 100%, respectively). The two other CCs with frequencies of 5%,
CC162 and CC35, also had high levels of strain coverage (91% and 85%, respectively)
but with broader confidence intervals (CI95, 53% to 100% and 29% to 92%, respec-
FIG 3 MATS coverage of NmB strains isolated in the United States during 2000 to 2008 by at least 1
antigen (95% CI) by year. Comparisons of point estimates of predicted strain coverage across groups did
not identify any statistically significant difference (P  0.567).
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tively), suggesting antigenic variability. Minor CCs had high strain coverage (between
50% and 89%), too.
Tables 2 and 3 report predicted strain coverage by genotype of the fHbp and NHBA
antigens, respectively. Within fHbp variant 1 (60% of the panel), fHbp covered 90% of
all major peptides corresponding to identification numbers (IDs) in the PubMLST
Neisseria sequence typing database with the exception of ID 13 (fHbp coverage, 24%
[CI95, 0% to 76%]; 6% of the isolates) and 81% of the minor IDs, for an overall 89%
coverage by fHbp. Within fHbp variants 2 and 3 (40% of the panel), fHbp provided
almost no coverage, and yet each antigenic variant was significantly (50% to 100%)
covered by other MenB-4C antigens, for an overall 83% coverage by non-fHbp MenB-4C
antigens. Within the eight major NHBA peptide IDs (IDs 5, 20, 2, 10, 29, 3, 21, and 1,
accounting for three-quarters of the circulating strains), NHBA provided consistently
high (84% to 100%) coverage. Coverage by NHBA for minor peptide IDs was also high
(69% [CI95, 41% to 84%]).
Due to the low number of isolates with levels of NadA MATS relative potency above
the positive bacterial threshold (PBT; see Materials and Methods), the relationship
between strain coverage and antigen genotype was not investigated for this antigen.
DISCUSSION
Molecular epidemiology is a component of bacterial surveillance programs that is
important for understanding the incidence and diversity of the Neisseria meningitidis






(n  442) % of total
Predicted coverage
(95% CI) by fHbp
Predicted coverage
(95% CI) by all antigens
1 1b 144 33 99 (99–99) 99 (99–99)
13 25 5.7 24 (0–76) 68 (52–92)
4 22 5.0 100 (91–100) 100 (100–100)
14 17 3.8 94 (47–100) 100 (94–100)
110 8 1.8 100 (100–100) 100 (100–100)
12 6 1.4 100 (17–100) 100 (67–100)
Other IDs 42 9.5 81 (57–86) 100 (74–100)
Total for variant 1 264 60 89 (77–95) 97 (89–99)
2 19 48 11 0 94 (56–98)
24 32 7.2 0 91 (41–100)
16 22 5.0 0 82 (27–86)
21 13 2.9 0 92 (62–100)
25 11 2.5 9.1 (0–9.1) 55 (36–64)
3 31 7 1.6 0 86 (0–86)
30 5 1.1 0 80 (60–100)
76 5 1.1 0 100 (100–100)
2/3 Other IDs 35 7.9 0 66 (43–83)
Total for variants 2 and 3 178 40 0.5 (0–0.5) 83 (46–91)
aID, identification number in PubMLST Neisseria sequence typing database. fHbp, factor H-binding protein.
bSubvariant included in MenB-4C multicomponent vaccine.
TABLE 1 Distribution of clonal complexes in the panel of 442 NmB strains
Clonal complex
Frequency
(n  442) % of total
Predicted % coverage (95% CI)
by all antigens
CC32 162 37 99 (98–100)
CC41/44 123 28 99 (73–100)
CC162 43 9.7 91 (53–100)
CC35 24 5.4 85 (29–92)
CC269 19 4.3 68 (32–89)
CC60 9 2.0 89 (67–100)
CC213 6 1.4 50 (33–50)
Unassigneda 25 5.7 64 (32–76)
Other (n  14) 31 7.0 68 (55–84)
aUnassigned, the sequence type (ST) of strains in this collection has been identified, but the ST belongs to
no clonal complex (CC).
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isolates collected in the United States. In order to predict the possible vaccine coverage
potential, it is critical to assess the expression of vaccine antigens in the representative
N. meningitidis isolates. A major limitation of the molecular approach to determine the
potential for strain coverage by a vaccine is that it has not been possible thus far to
obtain information about the expression levels of the protein encoded in the bacteria
from genetic data. Expression of the protein is necessary if the bacteria are to be
targeted by protective antibodies directed against the antigen of interest. Studies to
characterize the geographic and temporal distribution of the vaccine antigens among
the members of the N. meningitidis population in the United States are important to
understand the disease dynamics and strategies for deployment of MenB vaccines.
Considering the importance of antigen diversity and level of expression in predicting
MenB-4C vaccine coverage, MATS was used to assess the expression and cross-
reactivity to vaccine-induced antibodies of MenB-4C antigens among the isolates
selected in this study as representative of NmB meningococcal disease in the United
States.
MATS predicted MenB-4C vaccine coverage of over 90% of circulating NmB strains
in the United States. For the first time globally, strain coverage was estimated for a
significant period of time and was found to be consistent over a 9-year time period
(2000 to 2008). Among the MenB-4C vaccine antigens, NHBA alone was shown to
contribute to strain coverage in over 80% of the isolates in a consistent manner across
antigen genotypes. In contrast, fHbp coverage potential (53%) was restricted to the
variant 1 antigen genotypes, as the NmB isolates harboring fHbp variants 2 and 3 were
MATS negative for this antigen. Nonetheless, 83% of the fHbp variant 2/3 strains were
covered by other MenB-4C antigens, suggesting the importance of the multiple vaccine
components. MATS represents a conservative predictor of strain coverage in relation to
hSBA as it does not take into account synergy of combinations of antigens or the
contribution of other components present in the outer membrane vesicles (20, 29).
Also, MATS does not factor in the interactions between antigens present at levels below
the PBT. This is particularly relevant for MenB-4C vaccine as it contains multiple
components that may provide a greater synergistic effect even when the individual
components are present at levels below the bactericidal threshold (30).
Genetic diversity among the endemic NmB isolates is well documented (24). This
diversity is also seen in virulence genes that are vaccine targets. Possible changes in the
expression profiles of these genes in response to genotypic variations cannot be ruled
out. A change in the virulence factor’s structure might impact its immune reactivity,
jeopardizing the positive outcome of vaccination. Evidence for this can be drawn from
the MATS data obtained in this study with reference to fHbp, whose immune reactivity
was restricted by the variant class of this gene that corresponds to vaccine antigen.
Only those strains expressing variant 1 and its subclasses had expressed immune
susceptibility to the vaccine. In contrast, NHBA, despite the molecular variations in the
gene that encode the target peptides, was found to show immune reactivity to
antibodies induced by the major and minor peptide IDs.
Microbes are under constant evolutionary pressure posed by several factors, includ-
TABLE 3 Distribution of the most frequent neisserial heparin-binding antigen peptides in the panel of 442 strains
NHBA peptide IDa Frequency (n  442) % of total Predicted coverage (95% CI) by NHBA Predicted coverage (95% CI) by all antigens
5 127 29% 87% (31%–100%) 100% (98%–100%)
20 43 9.7% 98% (53%–100%) 98% (63%–100%)
2b 42 9.5% 100% (93%–100%) 100% (100%–100%)
10 29 6.6% 97% (55%–100%) 97% (55%–100%)
29 26 5.9% 92% (31%–100%) 96% (42%–100%)
3 26 5.9% 100% (88%–100%) 100% (96%–100%)
21 25 5.7% 84% (40%–92%) 88% (40%–96%)
1 18 4.1% 100% (100%–100%) 100% (100%–100%)
Other (n  47) 106 24% 50% (21%–71%) 69% (41%–84%)
aID, identification number in PubMLST Neisseria sequence typing database.
bPeptide included in the MenB-4C multicomponent vaccine.
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ing vaccines. Given the possibility of genotypic changes in a particular virulence gene
in response to vaccine pressure, an ideal vaccine should have inherent fail-safe mech-
anisms. One such strategy is to create a multicomponent vaccine such as MenB-4C. The
presence of multiple components in MenB-4C vaccine implies that coverage may be
maintained for strains that express multiple antigens in the event of mutation or loss
of expression of a single antigen. It was previously noted that the bactericidal activity
is increased for strains expressing two or more of the vaccine antigens at levels higher
than the positive bactericidal threshold (18).
Although this study was limited to the evaluation of NmB strains circulating up to
2009, the stability of the strain coverage prediction over the 9-year period investigated
suggests that no major differences should be expected in the ensuing years. Also, all
genetic lineages significantly represented in the country were covered at levels of
85%, suggesting that temporal oscillations in the frequency of clonal complexes
would not affect significantly the MenB-4C strain coverage. Postimplementation sur-
veillance capable of monitoring both genetic (antigens or full-genome sequencing) and
phenotypic (MATS) variations will be the key to quick adaptation of the public health
strategy to the potential response of the pathogen to vaccination (31), especially when
joined with dynamic modeling techniques that quantify in nearly real time the effec-
tiveness of immunization campaigns (32). Also, adopting the same tools and standards
for bacterial typing implementation worldwide, earlier epidemiological evidence from
one country could help in preventive adjustments of the implementation strategy in
other areas.
In September 2015, the United Kingdom was the first country to introduce MenB-4C
into the national infant immunization program, offering the vaccine to all infants born
after 1 July 2015, with a 2-plus-1 schedule at 2, 4, and 12 months and with two small
catch-up cohorts for infants born between 1 May and 30 June (3, 4, and 12 months and
4 and 12 months). A detailed multifaceted plan is in place for enhanced meningococcal
disease surveillance in England that will provide invaluable data on the usefulness of
MATS for monitoring vaccine impact, characterizing meningococci causing meningo-
coccal disease in both vaccinated and unvaccinated cohorts and the impact on
meningococcal disease in infants. The reduced infant schedule implemented from
September 2015 in the United Kingdom national immunization program provided the
first evidence of effectiveness of 83% for a two-dose vaccine against all NmB disease,
equivalent to a vaccine effectiveness of 94% against the most highly predicted NmB
disease-preventable strains (33). This vaccine effectiveness measured in the field ex-
ceeds significantly the MATS coverage predictions for the United Kingdom (67% in
2014/2015, representing the last year prior to mass vaccination). Considering the higher
(91%) MATS strain coverage predictions in the United States, the effectiveness of
MenB-4C vaccination in the United States could be potentially superior to the UK
results, particularly considering the burden of disease in the infant population for which
a direct link was established between MATS strain coverage and pooled hSBA titers and
individual seroprotection (21). Recently, the FDA approved the use of MenB-4C before
licensure to control several outbreaks in U.S. universities (34). The FDA subsequently
licensed MenB-4C for the age group of 10 to 25 years, and the ACIP recommended its
use for all persons of age 10 and older in high-risk groups (9). No cases of meningo-
coccal disease caused by N. meningitidis serogroup B have been reported among
vaccinated students, although the numbers were too low to allow statistically powered
determinations of efficacy (34). A recent immunogenicity study conducted among U.S.
college students during a NmB outbreak indicated that 87% to 100% of vaccinated
students showed immunoreactivity to reference NmB strains compared to modest
(66.1%) reactivity to the NmB outbreak strain (35). This difference in the levels of
immune reactivity among the MenB-4C seropositives reconfirms our incomplete un-
derstanding of strain susceptibility to vaccine-induced bactericidal activity and the
tendency of hSBA to underestimate the vaccine efficacy (36). Additional data regarding
the breadth and duration of protection provided by meningococcal B vaccine will be
key in the decision-making process pertaining to vaccine dosage and schedule.
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This report has provided a detailed breakdown of molecular characterization and
MATS results for U.S. invasive NmB strains, estimating a high level of strain coverage for
the MenB-4C vaccine in the United States. Overall, the data provide a useful baseline for
monitoring MenB-4C. However, due to anticipated changes in the distribution of clonal
complexes and antigen genotypes over time, continuous detailed surveillance and
monitoring of the antigen expression of circulating strains will be needed.
MATERIALS AND METHODS
Strain selection and classification. A representative panel of 442 U.S. NmB isolates collected by the
Active Bacterial Core surveillance (ABCs; CDC) in 2000 to 2008 were tested in MATS. Among these U.S.
isolates, representation of fHbp 1.1 was weighted to account for higher rates of serogroup B and overall
meningococcal disease occurring in Oregon. Multilocus sequence types, clonal complexes, and antigen
genotypes for these isolates had previously been determined (26). The U.S. isolates (n  442) tested in
this study included the major clonal complexes of endemic U.S. NmB strains. Clonal complexes CC32
(37%), CC41/44 (28%), and CC162 (9.7%) accounted for the majority of the strains (Table 1).
Genotypic classification of antigens. The classification of fHbp followed the scheme available on
the PubMLST Neisseria sequence typing database (http://pubmlst.org/neisseria/), which separates pep-
tide subvariants into three major variant classifications: variants 1, 2, and 3. Unique NHBA peptides and
nadA variants were numbered as previously described (37, 38). PorA subtyping had been previously
performed by PCR amplification and sequencing of the VR2 region of the gene (26). PorA variants had
been assigned therein according to variable region 2 (VR2) sequences on the PubMLST Neisseria
sequence typing database.
Meningococcal antigen typing system (MATS) ELISA. The MATS ELISA methodology (18), re-
agents, reference strains, and recombinant antigens were supplied by Novartis Vaccines and Diagnostics,
Siena, Italy (now part of the GSK group of companies). Briefly, bacteria were cultured overnight on
chocolate agar (BD Biosciences, San Jose, CA) and were suspended in Mueller-Hinton (MH) broth (BD
Biosciences, San Jose, CA) to an optical density at 600 nm (OD600) of 0.4. Empigen BB detergent (Sigma,
St. Louis, MO) was added to the bacterial suspension to reach a final dilution of 1:11, and this suspension
was incubated at 45°C for 1 h for bacterial inactivation. Twofold serial dilutions of bacterial extract in MH
broth with Empigen were carried out in ELISA plates (Costar, Corning, NY) that had been precoated with
rabbit polyclonal antibodies against fHbp, NHBA, or NadA. The plates were incubated for 1 h at 37°C and
then washed with phosphate-buffered saline (PBS)– 0.05% Tween. The plates were incubated for 1 h at
37°C with biotinylated antigen-specific rabbit polyclonal antibody to detect the primary antibody-bound
antigens. After being washed, the plates were developed with streptavidin-horseradish peroxidase (HRP)
(Jackson ImmunoResearch, West Grove, PA) and o-phenylenediamine dihydrochloride (OPD; Sigma). The
reaction was stopped with 4N H2SO4 and read at 492 nm. A reference strain for each antigen (H44/76 for
fHbp, NGH38 for NHBA, and 5/99 for NadA) was also included in the respective microtiter plates. Results
were analyzed with StatLIA software (Brendan Technologies, Carlsbad, CA). The relative potency (RP) for
each unknown strain was calculated by comparing the fit of the five-parameter logistic regression curves
to 2-fold serial dilutions of extracts from the reference strain and the unknown strain. The reference strain
for each antigen was assigned an arbitrary value of 100.
Estimation of NmB strain coverage. In a previous study, it was shown that the presence of at least
one antigen with a relative potency (RP) value greater than the positive bactericidal threshold (PBT; 0.021
for fHbp, 0.294 for NHBA, and 0.009 for NadA) or the presence of PorA P1.4 correlated with bactericidal
activity in the hSBA by pooled sera taken after immunization (18). Therefore, the MATS data could be
used to predict strain coverage by the multicomponent MenB-4C vaccine. Strains that did not meet these
criteria were deemed not covered. In this study, the predicted strain panel coverage was defined as the
proportion of strains with a MATS relative potency value greater than the positive bactericidal threshold
value for one or more antigens and/or with PorA P1.4. It should be noted that the PBT was set using
pooled sera from infants and that strain coverage predictions do not account for variations in the
individual seroresponses.
Statistical analysis. As described in the MATS interlaboratory standardization study (19), empirical
estimates of the 95% CIs for the positive bactericidal thresholds were derived with a log-normal
approximation based on the overall ranges of assay reproducibility (0.014 to 0.031 for fHbp, 0.169 to
0.511 for NHBA, and 0.004 to 0.019 for NadA). These values were used to define the 95% CIs of the strain
coverage data. No CI was calculated for coverage by the PorA antigen, as the typing was performed
genotypically (VR2  P1.4).
All statistical evaluations were performed using R statistical software (http://www.r-project.org)
version 2.13.1.
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